RFQ Attachment 6 - Questions and Answers Part 2.pdf

Genomics Sequencing Services for the NIAID Centralized Sequencing Program Notice ID: RFQ-NIAID-24-2224314

RFQ Attachment 6 – Questions & Answers Part 2

9/20/2024 – Amendment 4

Q1. Is Whole Genome Sequencing (WGS) – Duo and WGS – Trio no longer required? The RFQ – Attachment 5, does not have a provision for offering pricing for these tests as options. Could we please get some clarification?

A1. Duos and Trios are still expected with the same estimated frequency as described in RFQ Attachment 3 – QA (15%-20% of samples to be trios and 10%-15% to be duos). A single fixed price per genome considering these estimated frequencies is requested.

9/19/2024 – Amendment 3

With regard to the Quote Pricing Template:

Q1. Regarding Line# 1: “Base Quantity Genome Sequencing, 4-week turnaround time” – Is this Sequencing and return of RAW Data?

A1. Yes.

Q2. Lines 5–7: The Qty is the same (100) but identified as Option Quantity 3, Option Quantity 4 and Option Quantity 5. How are these items different?

A2. The type of work and the quantity on Line 5, Line 6, and Line 7 are not different. Lines 5-7 represent distinct option quantities for 100 additional genome sequencings with interpretation and report on each line. Among Lines 5-7, NIAID would have the option to exercise an additional 100, 200, or 300 genome sequencings with interpretation and report depending on how many of these options are required.

Q3. Lines 8-10: The Qty is the same (50) but identified as Option Quantity 6, Option Quantity 7 and Option Quantity 8. How are these items different?

A3. The type of work and the quantity on Line 8, Line 9, and Line 10 are not different. Lines 8-10 represent distinct option quantities for 50 additional genome sequencings with interpretation and report on each line. Among Lines 8-10, NIAID would have the option to exercise an additional 50, 100, or 150 genome sequencings with interpretation and report depending on how many of these options are required.

Q4. Lines 11-12: The Qty is the same (20) but identified as Option Quantity 9, Option Quantity 10 How are these items different?

A4. The type of work and the quantity on Line 11 and Line 12 are not different. Lines 11-12 represent distinct option quantities for 20 additional genome sequencings with interpretation and report on each line. Among Lines 11-12, NIAID would have the option to exercise an additional 20 or 40 genome sequencings with interpretation and report depending on how many of these options are required.

Q5. Lines 14-23: The Qty is the same (100) but identified as Option Quantity 12–21. This is the same as Lines 5–7. How are these items different?

A5. The type of work and the quantity on Lines 14-23 are not different from one another or Lines 5-

7. Lines 14-23 represent distinct option quantities for 100 additional genome sequencings with interpretation and report on each line. Among Lines 14-23, NIAID would have the option to exercise an additional 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 genome sequencings with interpretation and report depending on how many of these options are required.

Q6. Line 24: The Qty is (50) but identified as Option Quantity 22, which is the same as Lines 8-10.

How is this item different?

A6. The type of work and the quantity on 24 are not different from Lines 8-10. Line 24 represents a distinct option quantity for 50 additional genome sequencings with interpretation and report.

With Line 24, NIAID would have the option to exercise an additional 50 genome sequencings with interpretation and report if this option is required.